NovoCure Files 8-K: Regulation FD & Exhibits
Ticker: NVCR · Form: 8-K · Filed: May 20, 2024 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
Related Tickers: NVCR
TL;DR
NVCR filed an 8-K for standard disclosures, check exhibits for news.
AI Summary
NovoCure Ltd. filed an 8-K on May 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates NovoCure is meeting its regulatory disclosure obligations. Investors should review the exhibits for any potentially significant updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- NovoCure Ltd. (company) — Registrant
- 0001645113-24-000015 (filing_id) — Accession Number
- May 20, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for NovoCure Ltd.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the date of this filing?
The date of this filing is May 20, 2024.
What is NovoCure Ltd.'s principal executive office address?
NovoCure Ltd.'s principal executive office is located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
What is NovoCure Ltd.'s telephone number?
NovoCure Ltd.'s telephone number is +44 (0) 15 3475 6700.
What is the SEC file number for NovoCure Ltd.?
The SEC file number for NovoCure Ltd. is 001-37565.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-05-20 08:01:17
Filing Documents
- nvcr-20240520.htm (8-K) — 24KB
- 0001645113-24-000015.txt ( ) — 145KB
- nvcr-20240520.xsd (EX-101.SCH) — 2KB
- nvcr-20240520_lab.xml (EX-101.LAB) — 21KB
- nvcr-20240520_pre.xml (EX-101.PRE) — 12KB
- nvcr-20240520_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The abstract of the results of NovoCure Limited's ("Novocure") METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago will be made available on the ASCO website as a regular abstract on Thursday, May 23, 2024, at 5:00 PM (EDT). The METIS data will be presented on June 3, 2024, at 10:24 AM (CDT), during ASCO's Central Nervous System Tumors session. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: May 20, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer